Abstract | OBJECTIVE: METHODS: DMD boys aged 7 to 13 years, with confirmed deletions correctable by skipping exon 51 and ability to walk 200 to 400 m on 6 MWT, were randomized to weekly intravenous infusions of 30 or 50 mg/kg/wk eteplirsen or placebo for 24 weeks (n = 4/group). Placebo patients switched to 30 or 50 mg/kg eteplirsen (n=2/group) at week 25; treatment was open label thereafter. All patients had muscle biopsies at baseline and week 48. Efficacy included dystrophin-positive fibers and distance walked on the 6MWT. RESULTS: At week 24, the 30 mg/kg eteplirsen patients were biopsied, and percentage of dystrophin-positive fibers was increased to 23% of normal; no increases were detected in placebo-treated patients (p≤0.002). Even greater increases occurred at week 48 (52% and 43% in the 30 and 50 mg/kg cohorts, respectively), suggesting that dystrophin increases with longer treatment. Restoration of functional dystrophin was confirmed by detection of sarcoglycans and neuronal nitric oxide synthase at the sarcolemma. Ambulation-evaluable eteplirsen-treated patients experienced a 67.3 m benefit compared to placebo/delayed patients (p≤0.001). INTERPRETATION:
Eteplirsen restored dystrophin in the 30 and 50 mg/kg/wk cohorts, and in subsequently treated, placebo-controlled subjects. Duration, more than dose, accounted for dystrophin production, also resulting in ambulation stability. No severe adverse events were encountered.
|
Authors | Jerry R Mendell, Louise R Rodino-Klapac, Zarife Sahenk, Kandice Roush, Loren Bird, Linda P Lowes, Lindsay Alfano, Ann Maria Gomez, Sarah Lewis, Janaiah Kota, Vinod Malik, Kim Shontz, Christopher M Walker, Kevin M Flanigan, Marco Corridore, John R Kean, Hugh D Allen, Chris Shilling, Kathleen R Melia, Peter Sazani, Jay B Saoud, Edward M Kaye, Eteplirsen Study Group |
Journal | Annals of neurology
(Ann Neurol)
Vol. 74
Issue 5
Pg. 637-47
(Nov 2013)
ISSN: 1531-8249 [Electronic] United States |
PMID | 23907995
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Copyright | © 2013 American Neurological Association. |
Chemical References |
- Dystrophin
- Morpholinos
- Oligonucleotides
- eteplirsen
|
Topics |
- Adolescent
- Child
- Double-Blind Method
- Dystrophin
(genetics)
- Humans
- Male
- Morpholinos
- Muscle, Skeletal
(pathology)
- Muscular Dystrophy, Duchenne
(drug therapy, genetics, pathology)
- Mutation
- Oligonucleotides
(therapeutic use)
- Treatment Outcome
|